(Pozelimab)Biosimilar Reference Antibody-GS40561

货号：GS40561

Pozelimab is a fully human monoclonal IgG4 kappa antibody developed as a targeted therapy for complement-mediated diseases. Its primary mechanism of action is the specific and high-affinity binding to complement component C5, effectively blocking its cleavage into the pro-inflammatory fragments C5a and C5b. By inhibiting this central step in the complement cascade, pozelimab prevents the formation of the membrane attack complex (MAC, C5b-9) and the release of the potent anaphylatoxin C5a. This dual inhibition is designed to halt the uncontrolled complement activation that drives tissue damage in a range of rare and severe disorders.